Results 21 to 30 of about 65,470 (161)

COVID-19 en pacientes con esclerosis múltiple: estudio observacional retrospectivo en un centro de referencia colombiano

open access: yesActa Neurológica Colombiana, 2023
Introducción: en Colombia, la información sobre la frecuencia de presentación de la enfermedad por COVID-19 y sus desenlaces en personas con esclerosis múltiple (EM) es prácticamente inexistente.
Simón Cárdenas-Robledo   +3 more
doaj   +1 more source

Fertility preferences and unmet need for family planning in women with multiple sclerosis

open access: yesFrontiers in Neurology, 2022
BackgroundMost women with multiple sclerosis (MS) have childbearing potential. Although fertility and pregnancy are not affected by MS, the fertility preferences of women with MS can change due to the risk of complications for the mother and/or adverse ...
Lorena López-Reyes   +5 more
doaj   +1 more source

Aging and neuroinflammation: Changes in immune cell responses, axon integrity, and motor function in a viral model of progressive multiple sclerosis

open access: yes, 2022
Although aggravated multiple sclerosis (MS) disability has been reported in aged patients, the aging impact on immune cells remodeling within the CNS is not well understood.
Villar, Luisa M.   +6 more
core   +1 more source

Estudio del efecto del tratamiento con inmunoglobulinas por vía intravenosa en la neuromielitis óptica

open access: yesNeurología, 2013
Resumen: Objetivo: Evaluar la seguridad y tolerancia de las inmunoglobulinas por vía intravenosa (IgIV) para el tratamiento de la neuromielitis óptica (NMO).
M.J. Magraner, F. Coret, B. Casanova
doaj   +1 more source

The effect of intravenous immunoglobulin on neuromyelitis optica

open access: yesNeurología (English Edition), 2013
Objective: Evaluate safety and tolerance levels for intravenous immunoglobulins (IVIG) as treatment for neuromyelitis optica (NMO). Methods: Eight patients meeting Wingerchuk's revised diagnostic criteria were treated with IVIG every 2 months (0.7 g/kg ...
M.J. Magraner, F. Coret, B. Casanova
doaj   +1 more source

Recommendations for the clinical use of motor evoked potentials in multiple sclerosis

open access: yesNeurología (English Edition), 2013
Objective: To establish clinical guidelines for the clinical use and interpretation of motor evoked potentials (MEP) in diagnosing and monitoring patients with multiple sclerosis (MS).
V. Fernández   +18 more
doaj   +1 more source

Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine

open access: yesVaccines, 2023
This single-center study included 68 multiple sclerosis (MS) patients who received the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from one of several approved vaccine preparations in Spain.
Alexander Rodero-Romero   +11 more
doaj   +1 more source

Recomendaciones para la utilización clínica del estudio de potenciales evocados motores en la esclerosis múltiple

open access: yesNeurología, 2013
Resumen: Objetivo: Establecer una guía clínica para la utilización clínica del estudio de potenciales evocados motores (PEM) en el diagnóstico y el seguimiento de la esclerosis múltiple (EM).
V. Fernández   +18 more
doaj   +1 more source

A Polymorphism Within the MBP Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis

open access: yesFrontiers in Immunology, 2020
Myelin basic protein (MBP) is thought to be one of the key autoantigens in multiple sclerosis (MS) development. A recent study described the association of the single nucleotide polymorphism (SNP) rs12959006, within the MBP gene, with a higher risk of ...
Laura Espino-Paisán   +10 more
doaj   +1 more source

Natalizumab for relapsing-remitting multiple sclerosis

open access: yesNeurología (English Edition), 2011
Introduction: Natalizumab is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier and has been approved for the treatment of relapsing-remitting multiple sclerosis.
A. Horga, M. Tintoré
doaj   +1 more source

Home - About - Disclaimer - Privacy